IFNβ‐dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage

HyeonJoo Cheon(Cleveland Clinic Lerner College of Medicine), Elise Holvey-Bates(Cleveland Clinic Lerner College of Medicine), John W. Schoggins(Rockefeller University), Samuel C. Forster(Monash University), Paul J. Hertzog(Monash University), Naoko Imanaka(Rockefeller University), Charles M. Rice(Rockefeller University), Mark W. Jackson(Case Western Reserve University), Damian J. Junk(Case Western Reserve University), George R. Stark(Cleveland Clinic Lerner College of Medicine)
The EMBO Journal
September 24, 2013
Cited by 335Open Access
Full Text

Abstract

A single high dose of interferon-β (IFNβ) activates powerful cellular responses, in which many anti-viral, pro-apoptotic, and anti-proliferative proteins are highly expressed. Since some of these proteins are deleterious, cells downregulate this initial response rapidly. However, the expression of many anti-viral proteins that do no harm is sustained, prolonging a substantial part of the initial anti-viral response for days and also providing resistance to DNA damage. While the transcription factor ISGF3 (IRF9 and tyrosine-phosphorylated STATs 1 and 2) drives the first rapid response phase, the related factor un-phosphorylated ISGF3 (U-ISGF3), formed by IFNβ-induced high levels of IRF9 and STATs 1 and 2 without tyrosine phosphorylation, drives the second prolonged response. The U-ISGF3-induced anti-viral genes that show prolonged expression are driven by distinct IFN stimulated response elements (ISREs). Continuous exposure of cells to a low level of IFNβ, often seen in cancers, leads to steady-state increased expression of only the U-ISGF3-dependent proteins, with no sustained increase in other IFNβ-induced proteins, and to constitutive resistance to DNA damage.


Related Papers

No related papers found

Powered by citation graph analysis